Skip to main content
TNDM logo

TNDM · Tandem Diabetes Care Inc

Track TNDM — free
$20.07 +2.56 (+14.62%) At close · Nov 13
Market Cap
$1.40B
Shares
69.79M
Volume · Nov 13 4.4M Avg daily vol (3M) 2.21M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$20.07 Open$19.00 Day$18.53–20.26 52W close$12.82–28.26 Avg vol 30d2.5M Short int16.2M · 23.2% of shares · 7.6d Short vol49% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 18, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 13
Current report 8-K Events of Nov 12
Tandem Mobi tubeless system cleared for up to 7 days

Tandem Diabetes Care received 510(k) clearance for Tandem Mobi’s tubeless cartridge and infusion set, supporting up to 7 days of wear and 3 days of cartridge use. U.S. launch is planned for the first half of 2027.

Other events
3 source passages
On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear (1). Tubeless infusion set is cleared for up to 7 days of wear. Cartridge is cleared for 3 days of use. Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi is planned for the first half of 2027 in the United States. Open the document at this passage
Nov 5
Earnings call
Revenue grew 14%; leadership transition announced

Tandem reported worldwide revenue grew 14% year-over-year to $284 million, announced a CEO retirement at the end of 2026 and named Jeanette Bankus president and CEO.

2 source passages
worldwide revenue grew 14% year-over-year to $284 million we celebrate John Sheraton's accomplished tenure as he prepares to retire at the end of 2026, and we are thrilled to welcome Jeanette Bankus as Tandem's next president and CEO Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter sales reach $283.7 million, gross margin 57%

Tandem Diabetes Care reported third-quarter sales of $283.7 million, including $92.6 million internationally, and a 57% gross margin, compared with $249.3 million and 54%, amid continued inventory constraints from a key supplier.

Revenue $283.69M ▲ 13.8% Net loss $7.09M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. For the three months ended September 30, 2026, we shipped approximately 33,000 pumps worldwide. Sales were $283.7 million, which included $92.6 million of international sales. Sales were $249.3 million for the three months ended September 30, 2025, which included $73.6 million of international sales. The gross margins for the three months ended September 30, 2026 and 2025 were 57% and 54%, respectively. Open the document at this passage
Nov 5
Current report 8-K
Third-quarter sales rise 14% as operating loss narrows

Tandem Diabetes Care reported third-quarter sales of $283.7 million, up 14%, gross margin of 57% and an operating loss of $2.4 million versus $22.9 million. Adjusted EBITDA reached $18.0 million, compared with $2.8 million.

Financial results
5 source passages
Tandem Diabetes Care Announces Third Quarter 2026 Financial Results Sales: Worldwide sales increased 14% to $283.7 million, compared to $249.3 million on a reported basis and in constant currency(1). Gross profit was $160.4 million, compared to $134.3 million. Gross margin was 57%, compared to 54%. Operating loss was $2.4 million, or negative 1% of sales, compared to operating loss of $22.9 million, or negative 9% of sales. Adjusted EBITDA(1) was $18.0 million, or 6% of sales, compared to $2.8 million, or 1% of sales. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.08B
Trailing 12 months
Net income (TTM)
−$49.23M
Trailing 12 months
Revenue growth YoY
+13.8%
Year over year
Operating margin
-2.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$160.31M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.0%
Year over year · more shares
Price change (1Y)
+14.5%
Trailing year
Short interest
23.2%
Latest settlement · 7.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Tandem delivered 14% worldwide sales growth, a 57% gross margin and positive adjusted EBITDA, while reaffirming 2026 guidance and advancing Mobi Tubeless toward approval. The main offsets were slower pharmacy adoption extending revenue headwinds into 2027, a mid-to-high-single-digit 2027 revenue-growth starting point, continued operating losses, infusion-set shortages and international transition headwinds.

Bullish
  • + Worldwide sales grew 14% year over year to $283.7 million.
  • + Gross margin reached 57%, up 270 basis points from the prior-year quarter.
  • + Adjusted EBITDA reached 6% of sales, marking the fifth consecutive quarter of positive adjusted EBITDA.
  • + The company reaffirmed its 2026 guidance, including worldwide sales of approximately $1.065 billion to $1.085 billion.
  • + Pharmacy formulary coverage reached approximately 50% of U.S. lives, achieving the year-end access goal early.
  • + Mobi Tubeless remained in the late stages of FDA review and was expected to be approved in the fourth quarter, followed by limited customer use and expanded commercial availability in the first half of 2027.
Bearish
  • − Pharmacy adoption scaled more gradually than initially anticipated because of the time required to establish prescription workflows and change behaviors.
  • − Pharmacy pump adoption outpaced supply conversions, creating continued sales headwinds extending into 2027.
  • − Management indicated that mid-to-high-single-digit year-over-year revenue growth was a reasonable starting point for 2027.
  • − Tandem remained GAAP operating-loss-making, although the operating loss narrowed to $2.4 million from $22.9 million.
  • − Infusion-set supply shortages continued to affect the business into early 2027 despite improving availability in the third quarter.
  • − International direct-market transitions created a $3 million quarterly headwind and approximately $7 million of year-to-date impact.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +7%
above
Price vs 50-day avg +15%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +24%
trailing
6-month return +38%
trailing
YTD return −9%
this year
Relative strength +38%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow Accumulating
231 of 277 funds reported for Sep 30 · net +3.2M sh shares · +27 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
23.17% of shares out · ▲ +7.2% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
277 holders — mid 3-yr range
Squeeze score 96
high risk · 0–100
Fundamentals
Weak
Revenue growth +8%
Y/Y
Gross margin 54%
expanding
EPS growth −107%
Y/Y
Free cash flow $-29.7M
Balance sheet $219.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −55%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 6
Latest guidance · from the Earnings Call filed Aug 6, 2026
Gross margin · 2026 56% – 57%
Adjusted EBITDA margin · 2026 Non-GAAP Maintained 5% – 6%
May 7, 2026 5% – 6% changed to Aug 6, 2026 5% – 6%
Previous outlook earlier release · from the Earnings Call filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Gross margin · full year 2026 56% – 57%
Gross margins · full year 2026 56% – 57%
Adjusted EBITDA · full year 2026 5% – 6%
Pump ASPs outside the U.S. · for the rest of the year $2,800 – $2,900
Prior guidance period ended · from the Earnings Call filed Aug 6, 2026
Gross margin · third quarter 56%
Adjusted EBITDA margin · third quarter 2%
Guided vs delivered · last 6 settled
Worldwide sales second quarter
guided $255M
$254.56M Miss −0.2%
Sales full year
guided $1B
$1.01B Beat +1.5%
Sales year ending December 31, 2022
guided $835M – $845M
$801.22M Miss −4.6%
Sales year ending December 31, 2021
guided $685M – $695M
$702.8M Beat +1.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+7% Bullish
Price vs 50-day avg
+15% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow Accumulating
231 of 277 funds reported for Sep 30 · net +3.2M sh shares · +27 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
23.17% of shares out · ▲ +7.2% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
277 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $13 Now $20 · 47% Range high $28
vs 200-day avg +7% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $9.15M Six Months Ended June 30, 2026 —
Adjusted EBITDA margin non-GAAP 2% Six Months Ended June 30, 2026 —
Direct sales to customers as a percentage of international sales 13% the three months ended June 30, 2026 filing —
Non-GAAP free cash flow non-GAAP -$33.89M Six Months Ended June 30, 2026 —
Non-GAAP net loss non-GAAP -$41.56M Six Months Ended June 30, 2026 —
Non-GAAP operating loss non-GAAP -$31.23M Six Months Ended June 30, 2026 —
Non-GAAP operating margin non-GAAP -6% Six Months Ended June 30, 2026 —
pumps shipped worldwide 33,000 the three months ended June 30, 2026 filing —
Sales through the pharmacy channel as a percentage of United States sales 10% second quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TNDM
Tandem Diabetes Care Inc
this stock
$1.40B -8.7% +7.9% — 23.2%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
279
% held
117.3%
Reported
231 of 277
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
234
View
Short & Settlement
Short Interest Rising
Shares short
16.2M
Days to cover
7.6d
Change
+1.1M sh
View
Short Volume
Short vol %
49%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
20.0K
Value
$332.4K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
38.4%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Sep 29, 2026
View
Financials
Financials
Revenue (FY)
$1.0B
Net income (FY)
$-204.7M
EPS diluted
$-3.04
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
18

Tandem Diabetes Care received 510(k) clearance for Tandem Mobi’s tubeless cartridge and infusion set, supporting up to 7 days of wear and 3 days of cartridge use. U.S. launch is planned for the first half of 2027.

View
Proposed Sales
Value
$32.1K
Shares
1.7K
Filed
Oct 27, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 19, 2026
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Tandem Diabetes Care Announces Th…
Published
Nov 5, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
TNDM +18.7% +23.6% +38.0% +5.0% -8.7%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +16.1% +24.7% +37.5% +5.2% -19.3%
Key facts CIK 1438133 CUSIP 875372203 13F (30d) 212 filings 187 filers Visit website Investor relations